GB2504888B - Anti-Nerve growth factor antibodies and methods of preparing and using the same - Google Patents

Anti-Nerve growth factor antibodies and methods of preparing and using the same

Info

Publication number
GB2504888B
GB2504888B GB1320050.6A GB201320050A GB2504888B GB 2504888 B GB2504888 B GB 2504888B GB 201320050 A GB201320050 A GB 201320050A GB 2504888 B GB2504888 B GB 2504888B
Authority
GB
United Kingdom
Prior art keywords
preparing
methods
same
growth factor
nerve growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB1320050.6A
Other languages
English (en)
Other versions
GB2504888A (en
GB201320050D0 (en
Inventor
David Gearing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NVIP Pty Ltd
Original Assignee
NVIP Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NVIP Pty Ltd filed Critical NVIP Pty Ltd
Priority to GB1519606.6A priority Critical patent/GB2528811A/en
Publication of GB201320050D0 publication Critical patent/GB201320050D0/en
Publication of GB2504888A publication Critical patent/GB2504888A/en
Application granted granted Critical
Publication of GB2504888B publication Critical patent/GB2504888B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/467—Igs with modifications in the FR-residues only
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GB1320050.6A 2011-05-06 2012-05-08 Anti-Nerve growth factor antibodies and methods of preparing and using the same Active GB2504888B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1519606.6A GB2528811A (en) 2011-05-06 2012-05-08 Anti-nerve growth factor antibodies and methods of preparing and using the same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161483491P 2011-05-06 2011-05-06
US201161531439P 2011-09-06 2011-09-06
PCT/GB2012/051004 WO2012153123A1 (en) 2011-05-06 2012-05-08 Anti-nerve growth factor antibodies and methods of preparing and using the same

Publications (3)

Publication Number Publication Date
GB201320050D0 GB201320050D0 (en) 2013-12-25
GB2504888A GB2504888A (en) 2014-02-12
GB2504888B true GB2504888B (en) 2016-02-03

Family

ID=46168541

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1320050.6A Active GB2504888B (en) 2011-05-06 2012-05-08 Anti-Nerve growth factor antibodies and methods of preparing and using the same

Country Status (14)

Country Link
US (2) US20140170136A1 (cg-RX-API-DMAC10.html)
EP (2) EP2705056B1 (cg-RX-API-DMAC10.html)
JP (2) JP6181043B2 (cg-RX-API-DMAC10.html)
KR (1) KR101833465B1 (cg-RX-API-DMAC10.html)
CN (1) CN103764677A (cg-RX-API-DMAC10.html)
AU (1) AU2012252153B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013028652A8 (cg-RX-API-DMAC10.html)
CA (1) CA2834983C (cg-RX-API-DMAC10.html)
ES (1) ES2704007T3 (cg-RX-API-DMAC10.html)
GB (1) GB2504888B (cg-RX-API-DMAC10.html)
MY (1) MY160884A (cg-RX-API-DMAC10.html)
RU (1) RU2640252C2 (cg-RX-API-DMAC10.html)
SG (2) SG10201500957QA (cg-RX-API-DMAC10.html)
WO (1) WO2012153123A1 (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9783601B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
SG10201500957QA (en) * 2011-05-06 2015-04-29 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
AU2014368453B2 (en) 2013-12-20 2020-04-16 Intervet International B.V. Caninized murine anti-canine PD-1 antibodies
ES2853823T3 (es) 2014-09-30 2021-09-17 Intervet Int Bv Anticuerpos de PD-L1 que se unen a PD-L1 canino
CN104910274B (zh) * 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 抗人神经生长因子的中和性单克隆抗体12c11及其杂交瘤细胞株
CN104774265B (zh) * 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 抗人神经生长因子的中和性单克隆抗体11f1及其杂交瘤细胞株
WO2016190263A1 (ja) * 2015-05-22 2016-12-01 アステラス製薬株式会社 新規抗ヒトＮＧＦ抗体Ｆａｂフラグメント
ES3014160T3 (en) 2015-12-18 2025-04-21 Intervet Int Bv Caninized human antibodies to human and canine il-4r alpha
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
AU2018318440A1 (en) 2017-08-15 2020-02-13 Kindred Biosciences, Inc. IgG Fc variants for veterinary use
GB2578867A (en) * 2018-10-09 2020-06-03 Genome Res Ltd Animal models and therapeutic molecules
FR3087107A1 (fr) 2018-10-15 2020-04-17 Avent Inc. Compositions, systèmes, kits et méthodes d'ablation neurale
US20230391862A1 (en) * 2020-10-22 2023-12-07 Scout Bio, Inc. Method of suppressing immune response to vector-delivered therapeutic protein
US20240254245A1 (en) 2021-05-12 2024-08-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antigen binding molecule specifically binding to rankl and ngf, and medical use thereof
KR20240107201A (ko) 2021-08-31 2024-07-08 스카우트 바이오, 인코포레이티드 항원-결합 분자 및 이의 용도
EP4762084A1 (de) * 2023-08-17 2026-06-24 Gottfried Wilhelm Leibniz Universität Hannover (LUH) Nukleinsäuresequenz, vektor, screening-verfahren und verfahren zur herstellung von rekombinanten antikörpern

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2138512A1 (en) * 2003-12-24 2009-12-30 PanGenetics B.V. Humanized anti-NGF antibodies
WO2010027488A2 (en) * 2008-09-04 2010-03-11 Vet Therapeutics, Inc. Monoclonal antibodies
WO2012024650A2 (en) * 2010-08-19 2012-02-23 Abbott Laboratories Anti-ngf antibodies and their use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
CA2022959C (en) * 1989-08-10 2001-03-20 Hiroaki Maeda Cat-mouse heterohybridoma and gene fragment coding for constant region of feline immunoglobulin
JPH07503124A (ja) 1991-06-14 1995-04-06 ゾーマ・コーポレーション 微生物によって生産される抗体断片とそれらの複合体
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
KR101637908B1 (ko) * 2004-04-07 2016-07-11 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
AU2006294644A1 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
ES2514319T3 (es) 2009-05-04 2014-10-28 Abbvie Research B.V. Anticuerpos contra el factor de crecimiento nervioso (NGF) con estabilidad in vivo mejorada
EP2542258A4 (en) * 2010-03-04 2013-08-21 Vet Therapeutics Inc ON CD52 MONOCLONAL ANTIBODIES
BR112012022338A2 (pt) * 2010-03-04 2017-02-14 Vet Therapeutics Inc anticorpos monoclonais direcionados a cd20
SG10201500957QA (en) * 2011-05-06 2015-04-29 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2138512A1 (en) * 2003-12-24 2009-12-30 PanGenetics B.V. Humanized anti-NGF antibodies
WO2010027488A2 (en) * 2008-09-04 2010-03-11 Vet Therapeutics, Inc. Monoclonal antibodies
WO2012024650A2 (en) * 2010-08-19 2012-02-23 Abbott Laboratories Anti-ngf antibodies and their use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COVACEUSZACH, S. ; CASSETTA, A. ; KONAREV, P.V. ; GONFLONI, S. ; RUDOLPH, R. ; SVERGUN, D.I. ; LAMBA, D. ; CATTANEO, A.: "Dissecting NGF Interactions with TrkA and p75 Receptors by Structural and Functional Studies of an Anti-NGF Neutralizing Antibody", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 381, no. 4, 12 September 2008 (2008-09-12), United Kingdom, pages 881 - 896, XP023611489, ISSN: 0022-2836, DOI: 10.1016/j.jmb.2008.06.008 *
DATABASE Geneseq 30 December 2009 (2009-12-30), CATTANEO A, COVACEUSZACH S, LAMBA D: "Murine anti-NGF antibody heavy chain variable region, SEQ ID 2.", XP002680019, Database accession no. AXV23481 *
PELAT THIBAUT; HUST MICHAEL; THULLIER PHILIPPE: "Obtention and engineering of non-human primate (NHP) antibodies for therapeutics.", MINI REVIEWS IN MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBL, NL, vol. 9, no. 14, 1 December 2009 (2009-12-01), NL, pages 1633 - 1638, XP008134866, ISSN: 1389-5575, DOI: 10.2174/138955709791012283 *
Seminars in Immunology (1990); Vol 2, pp 457-466, "Humanisation of monoclonal antibodies for therapy", Gorman & Clark *

Also Published As

Publication number Publication date
AU2012252153A8 (en) 2013-12-19
CN103764677A (zh) 2014-04-30
BR112013028652A2 (pt) 2016-11-29
RU2640252C2 (ru) 2017-12-27
EP3502136A1 (en) 2019-06-26
SG194795A1 (en) 2013-12-30
JP2017123870A (ja) 2017-07-20
KR101833465B1 (ko) 2018-02-28
JP6526089B2 (ja) 2019-06-05
GB2504888A (en) 2014-02-12
KR20140041532A (ko) 2014-04-04
EP2705056A1 (en) 2014-03-12
ES2704007T3 (es) 2019-03-13
US20140170136A1 (en) 2014-06-19
EP2705056B1 (en) 2018-11-14
NZ617448A (en) 2015-01-30
BR112013028652A8 (pt) 2017-12-26
JP6181043B2 (ja) 2017-08-16
RU2013154307A (ru) 2015-06-20
US20190276525A1 (en) 2019-09-12
SG10201500957QA (en) 2015-04-29
CA2834983A1 (en) 2012-11-15
AU2012252153B2 (en) 2016-07-07
WO2012153123A1 (en) 2012-11-15
CA2834983C (en) 2020-11-17
GB201320050D0 (en) 2013-12-25
MY160884A (en) 2017-03-31
AU2012252153A1 (en) 2013-11-14
JP2014519318A (ja) 2014-08-14

Similar Documents

Publication Publication Date Title
GB2504887B (en) Anti-Nerve growth factor antibodies and methods of preparing and using the same
SG10201500960TA (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
GB201517547D0 (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
SG10201500957QA (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
ZA201308022B (en) Anti-cd40 antibodies and methods of use
ZA201403760B (en) Anti-cd98 antibodies and methods of use thereof
IL232055B (en) Anti-1htra antibodies and methods of use
GB201223276D0 (en) Antibodies and methods of producing same
ZA201501858B (en) Anti-mcam antibodies and associated methods of use
ZA201306451B (en) Anti-il-6 receptor antibodies and methods of use
IL224886A (en) Anti-ox40 antibodies and methods for their use
AP2013007135A0 (en) Anti-sclerostin antibody crystals and formulationsthereof
ZA201404675B (en) Anti-lrp5 antibodies and methods of use
SG11201502757QA (en) Anti-c16orf54 antibodies and methods of use thereof
EP2734234A4 (en) ANTI-CXCR4 ANTIBODIES AND METHOD OF USE THEREOF
EP2741745A4 (en) CABAZITAXEL FORMULATIONS AND METHODS OF PREPARATION
SG11201400405TA (en) Caninised antibodies and method for the production of same
SG11201400222RA (en) Caninised tumour necrosis factor antibodies and methods of using the same
ZA201300174B (en) Anti-neuropilin antibodies and methods of use
EP2785742A4 (en) ANTI-KDR ANTIBODIES AND METHOD OF USE THEREOF
HUS2200012I1 (hu) Idegi növekedési faktor elleni ellenanyagok és eljárások elõállításukra és alkalmazásukra
GB201519606D0 (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
GB2505352B (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
HK1193417A (en) Anti-fgfr4 antibodies and methods of use
HK1195326B (en) Anti-cd40 antibodies and methods of use

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20160519 AND 20160525

732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20220609 AND 20220615